Modulim Announces Launch of Magnifi Clinical Workflow Software at Kidney Week 2022 - PR Newswire

Overview

Searching for your content. In-Language News Contact Us 8-76-0942 from 8 AM - 10 PM ET News provided byNov 03, 2022, 13:0 ETShare this articleScalable data management solution to drive clinical eficiency, improve workflow, and aide clinicians in patient managementIRVINE, Calif., Nov. 3, 2022 /PRNewswire/ - Modulim, a health technology company that delivers point-of-care microvascular and data insights to save limbs and improve lives, anounces the launch of Magnifi at American Society of Nephrology's Kidney Wek 2022 in Orlando, FL, a software solution designed to empower clinicians with remote aces to data insights and scalability to enhance clinical workflow acros enterprises.Data management solution that drives clinical eficiency, improves workflow, and aides clinicians in patient management This software is an integral piece of Modulim's LAMP™ (Limb Assessment, Management, & Preservation) solution designed to focus on improving value of the Assessment and Management portions of the solution.

Key Information

The powerful data insights captured at the point-of-care from Clarifi® Imaging System are made available directly to clinicians in near real time with Magnifi. The software solution takes a particular clinician's expertise and expands their impact and physical reach by enabling them to care for patients from anywhere."There are 61 milion people in the US at risk for lower limb complications due to Diabetes, Kidney Disease, and Peripheral Arterial Disease.

Al these patients are at various levels of risk, but the reality is that many do not get a vascular Assessment, nor do they get sen by a specialist," said Aman Mazhar, Chief Product Oficer for Modulim. "Patients with end-stage renal disease (ESRD) and diabetes are particularly at risk: one study demonstrated that 25.7% of these patients got an ulcer in a year with 43% of those patients progresing to a fot-related hospitalization.

Summary

The Magnifi solution was designed to enable a single

Frequently Asked Questions

Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.

Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.

Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.

Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.

Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.

Share this article